Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urtica dioica pollen, derived from the common nettle, is an environmental allergen that can cause allergic rhinitis (pollinosis) in sensitized individuals. While historically considered to have low allergenic potential compared to other members of the Urticaceae family like Parietaria, recent studies have identified specific allergenic proteins within the pollen, including a thaumatin-like protein (osmotin) and pectinesterase. In clinical practice, extracts of the pollen are used as diagnostic agents in skin prick tests and nasal provocation tests to identify sensitization. It is also a candidate for allergen-specific immunotherapy (ASIT) to desensitize patients with confirmed nettle pollen allergy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on urtica dioica pollen.